Recent evidence in the field shows that circadian clock function should be considered a novel target to design new therapeutic strategies or improve the current approaches to treat high-grade gliomas (reviewed in Wagner et al. 2021a; Nettnin et al. 2023)) (Slat et al. 2017; Trebucq et al. 2021, 2024). This evidence concerns the gene CLOCK and glioma.